Man Group plc Invests $5.79 Million in Baxter International Inc. $BAX

Man Group plc bought a new stake in Baxter International Inc. (NYSE:BAX) during the 2nd quarter, HoldingsChannel reports. The firm bought 271,465 shares of the medical instruments supplier’s stock, valued at approximately $5,788,000.

Other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Baxter International during the second quarter worth $1,744,874,000. Pzena Investment Management LLC acquired a new position in Baxter International during the second quarter worth $1,392,098,000. Equity Investment Corp purchased a new stake in Baxter International in the 2nd quarter valued at $146,815,000. Bank of New York Mellon Corp acquired a new stake in shares of Baxter International in the 2nd quarter worth $68,036,000. Finally, Edmond DE Rothschild Holding S.A. purchased a new position in shares of Baxter International during the 2nd quarter worth $51,958,000. 90.19% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently weighed in on BAX. UBS Group increased their price target on shares of Baxter International from $19.00 to $25.00 and gave the company a “hold” rating in a research note on Tuesday, July 28th. The Goldman Sachs Group raised their target price on Baxter International from $19.00 to $21.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 15th. Zacks Research raised Baxter International from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Weiss Ratings upgraded Baxter International from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, July 31st. Finally, Wall Street Zen upgraded shares of Baxter International from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Two investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Baxter International presently has an average rating of “Hold” and a consensus target price of $22.45.

Baxter International Stock Performance

NYSE:BAX opened at $26.13 on Friday. The business’s fifty day moving average price is $24.24 and its 200 day moving average price is $20.55. The firm has a market capitalization of $13.51 billion, a PE ratio of -12.62, a price-to-earnings-growth ratio of 3.96 and a beta of 0.60. Baxter International Inc. has a 12 month low of $15.73 and a 12 month high of $30.00. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32.

Baxter International (NYSE:BAX) last posted its earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. The business had revenue of $2.96 billion during the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.59 EPS. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. On average, sell-side analysts anticipate that Baxter International Inc. will post 2.04 earnings per share for the current fiscal year.

Baxter International Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Friday, August 28th will be given a $0.01 dividend. The ex-dividend date is Friday, August 28th. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. Baxter International’s dividend payout ratio (DPR) is presently -1.93%.

Baxter International Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.